DE602005021667D1 - Inhibitoren der geschmacksrezeptoren zur verwendung in der behandlung von fettleibigkeit und zuckerkrankheit - Google Patents

Inhibitoren der geschmacksrezeptoren zur verwendung in der behandlung von fettleibigkeit und zuckerkrankheit

Info

Publication number
DE602005021667D1
DE602005021667D1 DE602005021667T DE602005021667T DE602005021667D1 DE 602005021667 D1 DE602005021667 D1 DE 602005021667D1 DE 602005021667 T DE602005021667 T DE 602005021667T DE 602005021667 T DE602005021667 T DE 602005021667T DE 602005021667 D1 DE602005021667 D1 DE 602005021667D1
Authority
DE
Germany
Prior art keywords
inhibitors
fatibility
treatment
sensor
taste receptors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005021667T
Other languages
English (en)
Inventor
Soraya Shirazi-Beechey
Jane Dyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vlaams Instituut voor Biotechnologie VIB
Original Assignee
Vlaams Instituut voor Biotechnologie VIB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vlaams Instituut voor Biotechnologie VIB filed Critical Vlaams Instituut voor Biotechnologie VIB
Publication of DE602005021667D1 publication Critical patent/DE602005021667D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE602005021667T 2004-09-22 2005-09-22 Inhibitoren der geschmacksrezeptoren zur verwendung in der behandlung von fettleibigkeit und zuckerkrankheit Active DE602005021667D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04077610 2004-09-22
PCT/EP2005/054760 WO2006032693A1 (en) 2004-09-22 2005-09-22 Intestinal epithelial glucose sensor

Publications (1)

Publication Number Publication Date
DE602005021667D1 true DE602005021667D1 (de) 2010-07-15

Family

ID=35457669

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005021667T Active DE602005021667D1 (de) 2004-09-22 2005-09-22 Inhibitoren der geschmacksrezeptoren zur verwendung in der behandlung von fettleibigkeit und zuckerkrankheit

Country Status (7)

Country Link
US (1) US20090196878A1 (de)
EP (1) EP1802324B1 (de)
AT (1) ATE469653T1 (de)
AU (1) AU2005286494B2 (de)
CA (1) CA2577632C (de)
DE (1) DE602005021667D1 (de)
WO (1) WO2006032693A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009020748A2 (en) * 2007-07-16 2009-02-12 Avaxia Biologics, Inc. Antibody therapy for modulating function of intestinal receptors
EP2725035A1 (de) 2007-10-02 2014-04-30 Avaxia Biologics, Inc. Antikörpertherapie zur Verwendung im Verdauungstrakt
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
US10849938B2 (en) 2017-09-13 2020-12-01 ZBiotics Company Gene expression system for probiotic microorganisms
GB201804816D0 (en) * 2018-03-26 2018-05-09 Anglia Ruskin Univ Higher Education Corporation Cancer treatment

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4642240A (en) * 1982-09-30 1987-02-10 General Foods Corporation Foodstuffs containing 3-aminobenzesulfonic acid as a sweetener inhibitor
GB8309855D0 (en) * 1983-04-12 1983-05-18 Tate & Lyle Plc Flavour modifiers
US4544565A (en) * 1984-03-29 1985-10-01 General Foods Corporation Foodstuffs containing sweetness inhibiting agents
US4910031A (en) * 1988-12-19 1990-03-20 Frito-Lay, Inc. Topped savory snack foods
JPH07184548A (ja) * 1993-12-28 1995-07-25 Meiji Seito Kk 口腔用組成物
US7803982B2 (en) * 2001-04-20 2010-09-28 The Mount Sinai School Of Medicine Of New York University T1R3 transgenic animals, cells and related methods
FR2825236B1 (fr) * 2001-05-30 2004-10-15 Lmd Composition orale comprenant un extrait d'ecorce d'albissia myriophylla et son utilisation pour supprimer ou reduire la fonction gustative
US7115284B2 (en) * 2003-08-11 2006-10-03 Ayurvedic-Life International, Llc Compositions for diabetes treatment and prophylaxis
US20050244810A1 (en) * 2003-09-29 2005-11-03 Egan Josephine M Taste signaling in gastrointestinal cells
US7541158B2 (en) * 2004-04-14 2009-06-02 Monell Chemical Senses Center Taste receptors of the T1R family from domestic dog
CA2636447A1 (en) * 2006-01-25 2007-08-02 Vib Vzw Method to control body weight

Also Published As

Publication number Publication date
CA2577632A1 (en) 2006-03-30
EP1802324A1 (de) 2007-07-04
AU2005286494A1 (en) 2006-03-30
ATE469653T1 (de) 2010-06-15
EP1802324B1 (de) 2010-06-02
WO2006032693A1 (en) 2006-03-30
AU2005286494B2 (en) 2011-06-23
US20090196878A1 (en) 2009-08-06
CA2577632C (en) 2014-04-01

Similar Documents

Publication Publication Date Title
MA32872B1 (fr) Traitement du diabete chez des patients dont la regulation glycemique est insuffisante malgre une therapie par un medicament antidiabetique oralou non oral
WO2008008286A3 (en) Substituted pyrazoles as ghrelin receptor antagonists
DE602006007093D1 (de) Kombinationstherapie zur Behandlung von Diabetes und dadurch bedingten Leiden sowie zur Behandlung von mittels Erhöhung des GLP-1-Spiegels im Blut verbesserten Leiden
SG163600A1 (en) Methods for the treatment of muscle loss
MX2009003305A (es) Inhibidores de co-transportador de glucosa de sodio 2 y metodo para su uso.
DE602005021667D1 (de) Inhibitoren der geschmacksrezeptoren zur verwendung in der behandlung von fettleibigkeit und zuckerkrankheit
IL194237A0 (en) Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators
FI20065593A0 (fi) Menetelmä galakto-oligosakkarideja sisältävien tuotteiden valmistamiseksi ja niiden käyttö
ATE486595T1 (de) Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur senkung der lipid- und blutzuckerspiegel
MX2009003658A (es) Compuestos heterociclicos que contienen nitrogeno biciclico para utilizarse como inhibidores de desaturasa de estearoilo-coa.
DE502006006466D1 (de) Eisen(iii) komplex-verbindungen zur oralen behandlung von eisenmangel bei patienten mit chronischen entzündlichen darmerkrankungen
EA201200975A1 (ru) Тиено[2,3-b]пиридиндионовые активаторы амфк и их терапевтическое применение
TW200616985A (en) Salicylthiazoles substituted by diphenylamine or diphenylamine derivatives, process for their preparation and their use
ATE552031T1 (de) Pharmazeutische zusammensetzungen enthaltend nicht-acyliertes ghrelin zur behandlung von insulinresistenz
WO2005115446A3 (en) Detection and use of prolylcarboxypeptidase
EP2010179A4 (de) Substituierte imidazol-4-carboxamide als cholecystokinin-1-rezeptor-modulatoren
EP2010178A4 (de) Substituierte imidazol-4-carboxamide als cholecystokinin-1-rezeptor-modulatoren
EP1882474A4 (de) Prophylaktisches/therapeutisches mittel für abweichungen im zucker/fettstoffwechsel
Bartolozzi The natural approach to osteoporosis
WO2006097933A3 (en) Method for monitoring changes in blood glucose level
ATE526023T1 (de) Pyridoxamin zur verwendung in der behandlung von diabetischer nephropathie bei typ ii diabetes
Imamura et al. Association between Na, K, and lipid intake in each meal and blood pressure
MX2009004112A (es) Imidazoles sustituidos como moduladores del receptor de bombesina subtipo-3.
Park et al. Postoperative delirium in elderly patients with osteoarthritis surgery: incidence and risk factors
NO20083636L (no) Asykliske sulfamid-derivater